Back to Search
Start Over
ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancer
- Source :
- American journal of clinical oncology. 11(6)
- Publication Year :
- 1988
-
Abstract
- The Eastern Cooperative Oncology Group (ECOG) entered 326 patients with advanced measurable colorectal cancer into four phase II drug or drug combination trials. Previously treated and chemotherapy-naive patients were eligible. Chlorozotocin was administered to 83 patients (51 previously treated), methyl-glyoxal-bis-guanylhydrozone (MGBG) to 90 patients (58 previously treated), and two regimens of the three-drug combination of cyclophosphamide, vincristine, and methotrexate (COM) to 153 patients (120 previously treated). The multidrug regimen had been developed specifically for previously treated patients. In this trial, chemotherapy-naive patients were no more likely to respond than were members of the previously-treated group. Even among previously untreated patients, response rates did not exceed 10% in any of these phase II programs. They are not recommended for further trials in patients with colorectal cancers.
- Subjects :
- Oncology
Drug
Cancer Research
Vincristine
medicine.medical_specialty
Mitoguazone
Cyclophosphamide
Colorectal cancer
medicine.medical_treatment
media_common.quotation_subject
Adenocarcinoma
Streptozocin
chemistry.chemical_compound
Internal medicine
Chlorozotocin
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
media_common
Chemotherapy
business.industry
Rectal Neoplasms
medicine.disease
Surgery
Regimen
Methotrexate
chemistry
Colonic Neoplasms
Drug Evaluation
business
medicine.drug
Subjects
Details
- ISSN :
- 02773732
- Volume :
- 11
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- American journal of clinical oncology
- Accession number :
- edsair.doi.dedup.....81b1a00f1043958bf86d18d54b11597a